The Clinical library includes videos, clinical papers and case studies which support the clinical trial data and real world experience of healthcare professionals using VARGATEF®.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
SUMMARY: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).
Patient case 1: Early progressing disease & administration of vargatef until PD
Watch the mechanism of action video
LUME-Lung 1 trial: efficacy, VARGATEF® + Docetaxel vs Placebo + Docetaxel